Alterity Therapeutics Ltd.

October 23, 2023

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attn: Cindy Polynice

Re: Alterity Therapeutics Ltd.
Registration Statement on Form F-3
File No. No. 333-274816

Ms. Polynice:

The undersigned, on behalf of Alterity Therapeutics Ltd. (“Alterity”), issuer of the securities covered by the above-referenced Registration Statement, hereby respectfully requests that the above-referenced Registration Statement be declared effective by the Securities and Exchange Commission at 4:00 p.m. Washington, D.C. time on Wednesday October 25, 2023, or as soon thereafter as possible.

Management of Alterity is aware of its responsibilities under the Securities Act of 1933 and the Securities Exchange Act of 1934 as they relate to the disposition of the securities covered by the above-referenced Registration Statement.

Thank you very much for your courtesy in this matter.

Very truly yours,

/s/ Kathryn Andrews

Kathryn Andrews
Chief Financial Officer